Hair Transplant Epigenetics Androgenetic Alopecia Research: The Twin Study Evidence, CAG Repeat Science, and What Dr. Keene’s Published Work Means for Your Treatment

Introduction: Why Two Identical Twins Can Have Completely Different Hair Loss Outcomes

Consider two identical twins. They share the same DNA, the same parents, and the same family history of hair loss. Yet by the age of 40, one twin has experienced significant balding while the other retains a thick, full head of hair. If genetics alone determined hair loss, this should be impossible. So what explains the difference?

The answer lies in a powerful biological principle: genetics loads the gun, but epigenetics pulls the trigger. It is in epigenetics, the layer of biological control that sits above the genome, where the real story of androgenetic alopecia (AGA) lives.

The scale of this condition is enormous. AGA affects up to 80% of men and 50% of women over their lifetimes, with an estimated 1.0 to 1.5 billion individuals affected worldwide, making it one of the most prevalent dermatological conditions on the planet.

Few clinicians are better positioned to explain the science behind it than Dr. Sharon Keene, MD, FISHRS. A former President of the International Society of Hair Restoration Surgery (ISHRS) and recipient of the 2013 Platinum Follicle Award for outstanding scientific research, Dr. Keene is a pioneering published researcher whose peer-reviewed work on epigenetics and AGA forms the authoritative backbone of this article. As an integral part of the team at Hair Transplant Specialists, her research bridges molecular science and real-world treatment.

This article translates Dr. Keene’s published research, including her landmark 2011 finasteride response study and her ISHRS Cyberchat series, into a clinically actionable framework. The goal is to explain what epigenetics actually means for hair loss and for treatment decisions, viewed through the lens of hair transplant epigenetics and androgenetic alopecia research.

From Genetics to Epigenetics: Why the Old Model of AGA Was Incomplete

For decades, AGA was considered a straightforward androgen-driven inherited condition, attributed primarily to DHT sensitivity and a family history of baldness. This model was useful but incomplete.

It could not explain why identical twins diverge in their hair loss. It could not explain why some people with strong family histories of baldness never lose significant hair. And it could not account for why hair loss sometimes accelerates dramatically after specific life events.

Modern genomic research has reframed the picture entirely. A 2026 peer-reviewed paper in Biology (MDPI) confirms that AGA is a complex polygenic disorder involving multiple biological pathways, including androgen signaling, hair follicle development, cell survival, and extracellular matrix remodeling.

Epigenetics refers to heritable changes in gene expression that do not alter the DNA sequence itself. It functions as a layer of biological switches sitting above the genome, capable of turning genes on or off.

Three primary epigenetic mechanisms are relevant to AGA:

1. DNA methylation: chemical tags that can silence or activate follicle growth genes.
2. Histone modification: structural changes to the protein spools around which DNA is wound, controlling which genes are accessible.
3. Non-coding RNAs: regulatory molecules, including microRNAs (such as miR-21 and miR-29a) and long non-coding RNAs, that modulate critical hair cycle signaling pathways.

The clinical implication is profound. Unlike DNA sequence changes, epigenetic modifications are potentially reversible and modifiable, which is precisely why the topic matters so much for treatment.

The Twin Study Evidence: What Identical Twins Teach Us About Epigenetic Hair Loss

Monozygotic, or identical, twin studies are the gold standard for separating genetic from epigenetic and environmental contributions to any condition. Because identical twins share the same genome, any difference between them must come from somewhere other than their DNA.

The core finding is striking: identical twins with the same genome have been documented to exhibit significantly different rates and patterns of hair loss, a divergence that cannot be explained by genetics alone.

This connects directly to Dr. Keene’s ISHRS Cyberchat series. Her three-part “Beyond Genetics in AGA” series, published between 2011 and 2012 in Hair Transplant Forum International, used identical twin survey data to establish that variant AGA rates in twins with identical DNA are strong evidence for epigenetic controls over hair loss expression.

What the twin divergence data reveals is that the timing, pattern, and severity of AGA are not simply written in the genes. They are shaped by how those genes are expressed over time in response to biological and environmental inputs.

A key concept here is epigenetic drift. As twins age and their life experiences diverge, their epigenomes diverge as well, accumulating different patterns of DNA methylation and histone modification that increasingly differentiate their biological characteristics, including hair loss.

The practical takeaway for patients is empowering: genetic risk for AGA sets a range of possible outcomes, but where a person lands within that range is substantially determined by epigenetic factors, many of which can be influenced.

The CAG Repeat Science: Dr. Keene’s Breakthrough Research on Androgen Receptor Sensitivity

To understand AGA at the molecular level, one must understand the androgen receptor (AR) gene. DHT (dihydrotestosterone) binds to androgen receptors in hair follicle dermal papilla cells, triggering the signaling cascade that progressively miniaturizes follicles.

Within exon 1 of the AR gene lies the CAG repeat polymorphism, a variable-length sequence of cytosine-adenine-guanine trinucleotide repeats. This sequence determines how sensitive a cell’s androgen receptor is to DHT stimulation.

The relationship is inverse: shorter CAG repeat lengths confer greater androgen sensitivity, meaning DHT signals are transduced more powerfully in follicle cells. Longer repeat lengths are associated with reduced androgen sensitivity.

This is where Dr. Keene’s landmark 2011 study, published in Dermatologic Therapy and co-authored with Andy Goren, made its mark. The pilot study examined genetic variations in the AR gene and finasteride response in women with AGA, mediated by epigenetics.

The key finding was significant. Women with fewer than 24 CAG repeats, indicating greater androgen sensitivity, were significantly more likely to respond to finasteride 1 mg/day compared to placebo and compared to women with 24 or more CAG repeats. Crucially, the response was not simply a function of CAG repeat count in isolation. It was mediated by epigenetic weighting of the CAG alleles, meaning the epigenome influenced how strongly the genetic variation was expressed in practice.

The clinical significance is hard to overstate. This research provided a biological explanation for why finasteride works dramatically well for some patients and produces minimal benefit for others, a question that had long frustrated clinicians and patients alike.

Dr. Keene’s pharmacogenomic research extended further, investigating variable minoxidil response based on sulfotransferase enzyme levels in hair follicles, another epigenetically influenced factor that helps explain differential drug responses.

What the CAG Repeat Research Means for Treatment Selection

If androgen receptor sensitivity, as indicated by CAG repeat length and its epigenetic expression, predicts finasteride response, then understanding a patient’s AR gene profile can inform whether anti-androgen therapy is likely to be effective.

This insight led Dr. Keene to serve as Chief Medical Officer of HairDx.com, the first company to offer genetic testing for androgenetic alopecia, a venture that grew directly from her research and represents a practical application of pharmacogenomic principles to hair loss treatment.

The broader principle is clear: one-size-fits-all treatment protocols ignore the biological reality that patients have meaningfully different epigenetic and pharmacogenomic profiles that predict their responses to standard therapies.

This is especially important for women. Dr. Keene’s research focused on female AGA patients, a population frequently underserved by hair loss research. A 2026 Biology (MDPI) paper confirms that women’s AGA has a partially distinct genetic and epigenetic risk architecture compared to men, underscoring the need for sex-specific approaches.

Rather than prescribing finasteride or minoxidil universally and waiting to see if they work, epigenetic and pharmacogenomic profiling can help predict responders versus non-responders before treatment begins. This also informs surgical planning. Understanding whether medical therapy is likely to be effective, and how aggressively AGA will progress, is essential for determining the timing, extent, and design of a hair transplant procedure.

How Epigenetics Controls the Hair Growth Cycle

The hair growth cycle has four phases: anagen (active growth, normally 2 to 6 years), catagen (transition), telogen (rest), and exogen (shedding). In AGA, the anagen phase progressively shortens to days or weeks, driving follicular miniaturization. Epigenetic mechanisms regulate this cycle at the molecular level.

The Wnt/β-Catenin Pathway: The Master Switch Epigenetics Controls

The Wnt/β-catenin signaling pathway functions as a critical, epigenetically regulated master switch for hair follicle cycling. Its activation initiates the anagen phase by stimulating hair follicle stem cell proliferation and differentiation.

In AGA, androgens suppress this pathway in dermal papilla cells, preventing normal stem cell differentiation and driving the progressive shortening of anagen. Non-coding RNAs, including microRNAs miR-21 and miR-29a and long non-coding RNAs such as H19 and AC010789.1, modulate Wnt/β-catenin and TGF-β signaling in hair follicle stem cells, representing epigenetic regulatory layers sitting above the androgen signaling cascade.

This pathway is also a primary target for next-generation AGA treatments. A 2025 Springer review confirms that Wnt/β-catenin, along with Sonic Hedgehog, BMP, and Notch signaling, represents a major therapeutic frontier.

Histone Marks and Chromatin Architecture in Hair Follicle Stem Cells

Histones are protein spools around which DNA is wound. Chemical modifications to these spools (acetylation, methylation, phosphorylation) determine whether nearby genes are accessible for transcription or locked away.

In hair follicle biology, the key histone marks are H3K27me3, H3K4me3, and H3K9ac, which serve as dynamic epigenetic regulators of hair follicle stem cell (HFSC) maintenance and function. Research published in 2026 in Scientific Data (Nature) documents how EZH1/EZH2-mediated H3K27 trimethylation is essential for hair follicle homeostasis.

This connects to the emerging concept of epigenetic age in hair follicles. Aging-associated epigenetic drift, including changes in DNA methylation clocks and histone code alterations, contributes to stem cell exhaustion in follicles, progressively impairing their ability to regenerate.

Lifestyle-Driven Epigenetic Accelerants: What Dr. Keene’s Research Identified

Dr. Keene’s Part III ISHRS Cyberchat (2012), titled “Evidence That Lifestyle Choices May Impact Hair Loss in Androgenetic Alopecia,” synthesized twin study data and epigenetic science to identify modifiable accelerants of AGA progression.

The mechanism linking lifestyle to epigenetics is well established. Chronic psychosocial stress, toxic exposures, and metabolic dysfunction generate oxidative stress and activate the hypothalamic-pituitary-adrenal (HPA) axis. Both drive epigenetic changes that can silence hair growth genes and accelerate follicular miniaturization.

Chronic Psychosocial Stress

Twin study evidence is compelling here. Twins who experienced major psychosocial stressors, including divorce and spousal death, showed accelerated AGA compared to their genetically identical counterparts who did not experience these events.

The biological mechanism involves chronic stress elevating cortisol and activating the HPA axis, which can epigenetically suppress hair follicle growth genes and shift the follicle prematurely from anagen to catagen. A 2026 BMC Public Health meta-analysis of 31 studies (11,224 AGA cases) confirmed that several psychosocial and metabolic risk factors are significant and modifiable contributors to AGA risk.

Cigarette Smoking and Heavy Alcohol Consumption

Smoking was confirmed as a significant AGA risk factor (odds ratio 1.46) in the 2026 BMC Public Health meta-analysis, and twin studies documented accelerated hair loss in smoking twins compared to non-smoking co-twins.

The epigenetic mechanism is straightforward. Both smoking and heavy alcohol consumption generate reactive oxygen species (ROS) and oxidative stress, which cause aberrant DNA methylation patterns and histone modifications that can silence hair follicle growth-promoting genes. Smoking cessation and alcohol moderation therefore represent actionable epigenetic interventions, not merely general health advice.

Unprotected Sunlight Exposure and UV-Induced Epigenetic Damage

Chronic unprotected sun exposure was identified in Dr. Keene’s research as a potential epigenetic accelerant of AGA, generating oxidative stress and DNA damage that can alter the epigenetic regulation of follicle cycling genes.

This is distinct from general dermatological advice to wear sunscreen. It carries a specific mechanistic rationale in the context of hair follicle epigenetics, underscoring the importance of scalp sun protection as part of a comprehensive hair health strategy.

Endocrine-Disrupting Chemicals: The Environmental Epigenetic Threat

Endocrine-disrupting chemicals (EDCs) were a focus of Dr. Keene’s Part II ISHRS research, an area virtually absent from much hair restoration clinic content despite growing scientific evidence.

EDCs are synthetic or natural compounds found in plastics, pesticides, personal care products, and industrial chemicals that interfere with hormonal signaling by mimicking, blocking, or altering the metabolism of endogenous hormones.

The proposed epigenetic mechanism is that EDCs can interfere with androgen receptor signaling and steroid hormone pathways by inducing aberrant DNA methylation and histone modifications in hormone-sensitive tissues, including hair follicle dermal papilla cells. In genetically susceptible individuals, EDC exposure could epigenetically amplify AGA by artificially elevating effective androgen signaling at the follicle level, accelerating miniaturization beyond what the underlying genetic risk would predict.

Awareness of common EDC sources, such as BPA in plastics, phthalates in personal care products, and certain pesticide residues, represents an underappreciated but potentially meaningful component of a comprehensive AGA management strategy. Dr. Keene’s published research on this topic gives Hair Transplant Specialists a uniquely authoritative voice in addressing the full biological picture of hair loss.

Nutrigenomics and AGA: How Diet Influences Hair Follicle Gene Expression

Nutrigenomics is the study of how dietary components influence gene expression through epigenetic mechanisms, a field directly relevant to AGA management.

Key nutritional deficiencies associated with increased AGA risk and epigenetic dysregulation include vitamin B complex, vitamin D, iron, selenium, and zinc, all of which have been associated with impaired hair follicle function. Dr. Keene’s published research on vitamin D deficiency and hair loss (2022) reflects the practice’s ongoing engagement with nutritional epigenetics in AGA.

The mechanism is elegant. Micronutrients serve as cofactors for epigenetic enzymes such as DNA methyltransferases and histone deacetylases, and deficiencies can impair the normal epigenetic regulation of hair cycle genes.

This means nutritional assessment and targeted supplementation are not merely adjunct wellness recommendations; they are potentially meaningful epigenetic interventions that support the biological environment in which hair follicles must function. The 2026 BMC Public Health meta-analysis also confirmed insulin resistance as a significant AGA risk factor, and metabolic health, substantially influenced by diet, represents a modifiable epigenetic lever for AGA management.

The Emerging Epigenetic Treatment Frontier: What the Research Pipeline Means for Patients

The global epigenetics market was valued at USD 1.84 billion in 2023 and is projected to reach USD 6.77 billion by 2033, with over 35 epigenetic therapies currently in clinical trials and growing diversification into dermatology and hair loss.

More than 100 therapeutic candidates from 80 or more companies are now in development for AGA, spanning RNA interference, PROTAC-based androgen receptor degraders, metabolic stem cell activators, and cell therapies, many of which target epigenetically regulated pathways.

The urgency is real. A 2025 International Journal of Molecular Sciences review noted that despite the widespread use of minoxidil and finasteride, their clinical efficacy remains limited for many patients, underscoring the need for next-generation epigenetic approaches.

Wnt Pathway Activators and Follicle Neogenesis

Since androgens in AGA suppress Wnt/β-catenin signaling, pharmacological activation of this pathway represents a targeted epigenetic intervention to restore normal anagen initiation. A 2025 Cells (MDPI) review on follicle neogenesis notes that stem cell biology advances are making follicle regeneration in adult humans increasingly feasible, with Wnt/β-catenin modulation as a central mechanism.

This connects to existing non-surgical treatments offered at Hair Transplant Specialists. PRP therapy and stem cell/exosome therapies may epigenetically reactivate dormant follicle stem cells, partly through Wnt pathway modulation, a mechanistic explanation that adds important scientific context to these treatment options. Patients interested in non-surgical hair loss treatment without medication may find these emerging approaches particularly relevant.

Epigenetic Reprogramming: The Turn Biotechnologies ERA Platform

Turn Biotechnologies’ ERA (Epigenetic Reprogramming of Age) platform, developed at Stanford University, uses mRNA-encoded epigenetic reprogramming factors delivered via lipid nanoparticles to restore youthful gene expression patterns in hair follicle stem cells.

The scientific rationale targets the concept of epigenetic age by reversing aging-associated epigenetic drift, including DNA methylation clock changes and histone code alterations, that contributes to stem cell exhaustion. The company is targeting an IND filing with the FDA, representing the most advanced epigenetic reprogramming approach specifically targeting AGA.

While this technology is not yet clinically available, it represents the direction the field is moving. Understanding this trajectory helps patients make informed decisions about their current treatment options in the context of what may be available in the future.

CRISPR Epigenome Editing and Partial Reprogramming Strategies

Unlike traditional CRISPR gene editing, CRISPR-dCas9 epigenome editing uses a catalytically inactive Cas9 to deliver epigenetic modifiers, such as HDAC inhibitors and DNA methyltransferase inhibitors, to specific genomic locations. This enables precise, targeted epigenetic changes without altering the DNA sequence.

A 2025 MedComm (Wiley) review on epigenetic rejuvenation strategies notes that partial OSKM reprogramming, HDAC inhibitors, and NAD+/sirtuin boosters are being evaluated for resetting epigenetic age and restoring tissue homeostasis, with direct relevance to hair follicle aging. These approaches are earlier in development but represent a scientifically credible pathway toward reversing epigenetic aging rather than merely slowing it.

Connecting the Science to Your Treatment: A Clinically Actionable Framework

Epigenetic science now allows patients and clinicians to ask, and increasingly answer, a series of meaningful questions. The following framework translates that science into practical steps.

Step 1: Assess Your Epigenetic Risk Profile

Understanding AGA risk now goes beyond family history. AR gene CAG repeat length, pharmacogenomic factors like sulfotransferase enzyme levels (for minoxidil response), and epigenetic accelerant exposure all contribute to a more complete picture.

Dr. Keene’s HairDx.com work is a practical example of how genetic and epigenetic profiling can be applied clinically to predict treatment response. A thorough consultation with a physician-researcher like Dr. Keene, who understands both the surgical and molecular dimensions of AGA, provides a qualitatively different level of treatment planning than a consultation focused solely on graft counts and hairline design.

Step 2: Address Modifiable Epigenetic Accelerants

The interventions supported by Dr. Keene’s published research include stress management, smoking cessation, alcohol moderation, UV protection, EDC reduction, and nutritional optimization.

These are not generic wellness suggestions; they are epigenetically grounded interventions with a specific mechanistic rationale for AGA patients. Addressing these factors may slow the rate of ongoing hair loss, which is critical for long-term surgical planning. A transplant performed without addressing progressive loss may require additional procedures as untreated follicles continue to miniaturize.

Step 3: Select Medical Therapy Based on Predicted Response

Applying Dr. Keene’s CAG repeat research, patients with shorter CAG repeat lengths (greater androgen sensitivity) are more likely to respond to finasteride. This makes AR gene profiling a rational basis for treatment selection rather than a trial-and-error approach.

The practice’s data shows 85% or higher stabilization or improvement after 5 years in appropriate candidates, a figure that becomes far more meaningful when one understands which patients are likely to fall within that group. For predicted responders, combining finasteride and/or minoxidil with surgical restoration and non-surgical treatments (PRP, Alma TED, LLLT) addresses the condition from multiple biological angles simultaneously.

Step 4: Time Surgical Intervention Strategically

Because AGA progression is not purely genetic and can be influenced by modifiable factors, stabilizing the epigenetic environment before surgery, through medical therapy, lifestyle modification, and nutritional optimization, can improve long-term surgical outcomes.

A patient with multiple epigenetic accelerants (smoking, chronic stress, poor nutrition) who has not addressed these factors may experience faster ongoing loss that compromises the long-term appearance of a transplant. Hair Transplant Specialists’ comprehensive consultation process, informed by Dr. Keene’s research background, evaluates the full biological picture rather than simply the current state of hair loss.

Why Dr. Keene’s Published Research Sets Hair Transplant Specialists Apart

Dr. Keene’s credentials in this space are exceptional: former ISHRS President (2014 to 2015), 2013 Platinum Follicle Award recipient for outstanding scientific research, published researcher in peer-reviewed journals, and a physician who has actively translated epigenetic science into clinical practice.

The 2011 Dermatologic Therapy paper was not a theoretical review but a clinical pilot study with real patient data. It represents the kind of evidence-based approach that distinguishes Dr. Keene’s practice from clinics that treat hair restoration as a purely technical surgical exercise.

Her ISHRS Cyberchat series stands as a landmark contribution to patient and clinician education. By publishing a three-part series specifically addressing epigenetics and lifestyle factors in AGA, Dr. Keene established a framework that the broader field is only now beginning to fully appreciate.

The breadth of her research portfolio is equally notable, spanning FUE technique optimization and safe excision limits, photobiomodulation, vitamin D deficiency, and epigenetics. Her published work reflects a physician who understands hair loss as a complex biological phenomenon requiring multidimensional solutions.

Very few hair restoration surgeons possess both the surgical expertise to perform world-class transplant procedures and the research background to understand and apply the molecular biology of hair follicle epigenetics. Dr. Keene represents this rare intersection.

Conclusion: Epigenetics Changes What Hair Loss Treatment Can Be

AGA is not simply a genetic fate. It is an epigenetically modulated condition in which the interplay of DNA, biological environment, and lifestyle choices determines actual hair loss outcomes.

The key insights are clear. Identical twin divergence data proves that genetics alone does not determine AGA expression. CAG repeat polymorphisms and their epigenetic weighting predict treatment response. Lifestyle factors are genuine biological accelerants with mechanistic explanations. And the emerging treatment pipeline is increasingly targeting epigenetic pathways.

Understanding epigenetics transforms hair loss treatment from a reactive, one-size-fits-all approach into a proactive, personalized strategy. It can predict who will respond to which treatments and how to optimize the biological environment for the best possible outcomes.

While epigenetic reprogramming therapies like Turn Biotechnologies’ ERA platform are not yet clinically available, the science is advancing rapidly. Patients who understand this landscape are better positioned to make informed decisions about their treatment journey today.

The future of hair restoration is not just about moving follicles from one location to another. It is about understanding and influencing the biological language that determines whether those follicles thrive, and Dr. Keene’s published research has been part of writing that language.

Ready to Understand Your Hair Loss at a Deeper Level? Schedule a Consultation

If this article has shown that hair loss is more complex, and more treatable, than commonly believed, a consultation with Hair Transplant Specialists can help patients understand their individual epigenetic and biological profile.

Consultations at Hair Transplant Specialists are informed by Dr. Keene’s research background and the practice’s commitment to understanding each patient’s unique hair loss journey rather than simply prescribing a standard protocol. From epigenetically informed medical therapy selection to surgical planning that accounts for long-term progression, the practice’s approach reflects the science described throughout this article.

To begin the conversation, contact Hair Transplant Specialists at (651) 393-5399 or visit INeedMoreHair.com to schedule a consultation at the Eagan, MN location. Consultations are available Monday through Thursday from 9:00 AM to 5:00 PM, Friday from 9:00 AM to 3:00 PM, and by appointment on weekends.

Every hair loss journey is unique, and understanding the epigenetic science behind it is the first step toward a treatment plan that truly fits.